Toxic Epidermal Necrolysis and Stevens Johnson Syndrome: Our Current Understanding

Roujeau, 1994, Severe adverse cutaneous reactions to drugs, N. Engl. J. Med., 331, 1272, 10.1056/NEJM199411103311906

Assier, 1995, Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes, Arch. Derm., 131, 539, 10.1001/archderm.1995.01690170041005

Bastuji-Garin, 1993, Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, Arch. Dermatol., 129, 92, 10.1001/archderm.1993.01680220104023

Auquier-Dunant, 2002, Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study, Arch. Dermatol., 138, 1019, 10.1001/archderm.138.8.1019

Lyell, 1956, Toxic epidermal necrolysis: an eruption resembling scalding of the skin, Br. J. Dermatol., 68, 355, 10.1111/j.1365-2133.1956.tb12766.x

Achten, 1970, Lyell’s toxic epidermal necrolysis : histologic aspects, Arch. Belg. Dermatol. Syphiligr., 26, 97

Roujeau, 1990, Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 19811985, Arch. Dermatol., 126, 37, 10.1001/archderm.1990.01670250043005

Revuz, 1987, Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients, Arch. Dermatol., 123, 1160, 10.1001/archderm.1987.01660330071012

Bastuji-Garin, 2000, SCORTEN : a severity-of-illness score for toxic epidermal necrolysis, J. Invest. Dermatol., 115, 149, 10.1046/j.1523-1747.2000.00061.x

Trent, 2004, Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States, Arch. Dermatol., 140, 890, 10.1001/archderm.140.7.890

Roujeau, 1990, Toxic epidermal necrolysis(Lyell syndrome), J. Am. Acad. Dermatol., 23, 1039, 10.1016/0190-9622(90)70333-D

Rzany, 1993, Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany, Arch. Dermatol., 129, 1059, 10.1001/archderm.1993.01680290135026

Duncan, 1999, Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital, J. Am. Acad. Dermatol., 40, 493, 10.1016/S0190-9622(99)70508-6

Roujeau, 1995, Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, N. Engl. J. Med., 333, 1600, 10.1056/NEJM199512143332404

Garcia-Doval, 2000, Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death ?, Arch. Dermatol., 136, 323, 10.1001/archderm.136.3.323

Spielberg, 1981, Predisposition to phenytoin hepatotoxicity assessed in vitro, N. Engl. J. Med., 305, 722, 10.1056/NEJM198109243051302

Shear, 1986, Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity, Ann. Intern. Med., 105, 179, 10.7326/0003-4819-105-2-179

Wolkenstein, 1995, Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants, Arch. Dermatol., 131, 544, 10.1001/archderm.1995.01690170046006

Wolkenstein, 1995, A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome, Pharmacogenetics, 5, 255, 10.1097/00008571-199508000-00011

Dietrich, 1995, Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis, Exp. Dermatol., 4, 313, 10.1111/j.1600-0625.1995.tb00211.x

Roujeau, 1987, Genetic susceptibility to toxic epidermal ne- crolysis, Arch. Dermatol., 123, 1171, 10.1001/archderm.1987.01660330082014

Hung, 2005, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc. Natl. Acad. Sci. U. S. A., 102, 4134, 10.1073/pnas.0409500102

Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a

Merot, 1986, Lymphocyte subsets and Langerhans’ cells in toxic epidermal ne- crolysis, Report of a case. Arch. Dermatol., 122, 455, 10.1001/archderm.1986.01660160111029

Villada, 1992, Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases, Arch. Dermatol., 128, 50, 10.1001/archderm.1992.01680110060006

Correia, 1993, Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement, Arch. Dermatol., 129, 466, 10.1001/archderm.1993.01680250078010

Nassif, 2004, Toxic epidermal necrolysis : effector cells are drug-specific cytotoxic T cells, J. Allergy Clin. Immunol., 114, 1209, 10.1016/j.jaci.2004.07.047

Nassif, 2002, Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis, J. Invest. Dermatol., 118, 728, 10.1046/j.1523-1747.2002.01622.x

Nassif, 2004, Evaluation of the potential role of cytokines in toxic epidermal necrolysis, J. Invest. Dermatol., 123, 850, 10.1111/j.0022-202X.2004.23439.x

Paul, 1996, Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis, Br. J. Dermatol., 134, 710, 10.1111/j.1365-2133.1996.tb06976.x

Wehrli, 2000, Death receptors in cutaneous biology and disease, J. Invest. Dermatol., 115, 141, 10.1046/j.1523-1747.2000.00037.x

Viard, 1998, Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin, Science, 282, 490, 10.1126/science.282.5388.490

Ito, 2004, Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression, Clin. Exp. Dermatol, 29, 679, 10.1111/j.1365-2230.2004.01635.x

Viard-Leveugle, 2003, Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions, J. Biol. Chem., 278, 16183, 10.1074/jbc.M212188200

Heng, 1991, Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiologic aspects, J. Am. Acad. Dermatol., 25, 778, 10.1016/S0190-9622(08)80969-3

Hewitt, 1992, Toxic epidermal necrolysis treated with cyclosporin, Clin. Exp. Dermatol., 17, 264, 10.1111/j.1365-2230.1992.tb02163.x

Arevalo, 2000, Treatment of toxic epidermal necrolysis with cyclosporin A, J. Trauma., 48, 473, 10.1097/00005373-200003000-00017

Trautmann, 1998, Severe bullous drug reactions treated successfully with cyclophosphamide [letter], Br. J. Dermatol., 139, 1127, 10.1046/j.1365-2133.1998.2576n.x

Kamanbroo, 1985, Plasmapheresis in severe drug-induced toxic epidermal necrolysis, Arch. Dermatol., 121, 1548, 10.1001/archderm.1985.01660120074023

Redondo, 1997, Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis-treatment with N-acetylcysteine, Br. J. Dermatol., 136, 645, 10.1111/j.1365-2133.1997.tb02175.x

Wolkenstein, 1998, Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis, Lancet, 352, 1586, 10.1016/S0140-6736(98)02197-7

Prins, 2003, Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases, Arch. Dermatol., 139, 26, 10.1001/archderm.139.1.26

Trent, 2003, Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience, Arch. Dermatol., 139, 39, 10.1001/archderm.139.1.39

Bachot, 2003, Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression, Arch. Dermatol., 139, 33, 10.1001/archderm.139.1.33

Campione, 2003, High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis, Acta Derm. Venereol., 83, 430

Shortt, 2004, Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis, J. Burn. Care Rehabil., 25, 246, 10.1097/01.BCR.0000124746.33279.86

Brown, 2004, Toxic epidermal necrolysis : does immunoglobulin make a difference?, J. Burn. Care Rehabil., 25, 81, 10.1097/01.BCR.0000105096.93526.27

Al-Mutairi, 2004, Prospective, non-comparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis, Int. J. Dermatol., 43, 847, 10.1111/j.1365-4632.2004.02048.x

Tan, 2005, High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series, J. Dermatol., 32, 1, 10.1111/j.1346-8138.2005.tb00704.x

Prins, 2003, Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study, Dermatology, 207, 96, 10.1159/000070957